Thomas J. Hudzik
Principal Executive
ALA BioPharma Consulting
Dr. Hudzik serves as the principal executive of ALA.BioPharma, a consulting and research company. He previously held the position of Director of Translational Neuroscience at the cell and gene therapy company BlueRock Therapeutics, and has occupied leadership roles at GSK, AbbVie, Abbott Labs and AstraZeneca. Over the past decade, his work has centred on risk assessment and management for therapeutics with central nervous system activity. At AstraZeneca and BlueRock Therapeutics, he led teams that identified and advanced five candidate therapeutics into clinical trials. He is an active member of the College on Problems of Drug Dependence, holds a leadership role in the Cross-Company Abuse Liability Assessment Council, and has been active in the Behavioral Pharmacology Society, the American Society for Pharmacology and Experimental Therapeutics, and the Society for Neuroscience. He has reviewed numerous NIH grant applications and journal articles over a career spanning 30 years.
His area of expertise lies in Psychopharmacology of neurologic and psychiatric diseases, including substance use disorders, animal models, behavioral pharmacology, stroke, epilepsy, anorexia, schizophrenia, depression, bipolar disorder, anxiety disorders, pain and its comorbidities with psychiatric disorders, post-traumatic stress disorder and neuroprotection.
